Safety of Percutaneous Endoscopic Gastrostomy Placement in Patients With SARS-CoV-2 Infection.

IF 1.7 Q4 GASTROENTEROLOGY & HEPATOLOGY Gastroenterology Research Pub Date : 2022-10-01 Epub Date: 2022-10-19 DOI:10.14740/gr1533
Ayushi Shah, Zunirah Ahmed, Fadl Zeineddine, Eamonn M M Quigley
{"title":"Safety of Percutaneous Endoscopic Gastrostomy Placement in Patients With SARS-CoV-2 Infection.","authors":"Ayushi Shah, Zunirah Ahmed, Fadl Zeineddine, Eamonn M M Quigley","doi":"10.14740/gr1533","DOIUrl":null,"url":null,"abstract":"Background Coronavirus disease 2019 (COVID-19) can lead to ventilator-dependent chronic respiratory failure and a need for tube feeding. Percutaneous endoscopic gastrostomy (PEG) placement provides more sustainable longer-term enteral access with fewer side effects compared to the long-term nasogastric tube placement. Bleeding is a recognized complication of PEG placement, and many COVID-19 patients are on antiplatelets/anticoagulants, yet minimal data exist on the safety of PEG tube placement in this context. Methods A retrospective chart review identified patients who underwent PEG placement between January 2020 and January 2021 at a single institution. Success was defined as PEG placement and use to provide enteral nutrition with no complications requiring removal within 4 weeks. Results Thirty-six patients with and 104 age- and sex-matched patients without COVID-19 infection were included. More COVID-19 patients were obese, on anticoagulants, had low serum albumin levels and had a tracheostomy in place. Of those patients, 8.3% with COVID-19 developed PEG-related complications compared to 16.3% without (P = 0.28). PEG success rates in patients with and without COVID-19 were similar at 97.2% and 92.3%, respectively (P = 0.44). Conclusion PEG tube placement is comparatively safe in COVID-19 patients who need long-term enteral access.","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 5","pages":"263-267"},"PeriodicalIF":1.7000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c3/2b/gr-15-263.PMC9635784.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/gr1533","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/19 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background Coronavirus disease 2019 (COVID-19) can lead to ventilator-dependent chronic respiratory failure and a need for tube feeding. Percutaneous endoscopic gastrostomy (PEG) placement provides more sustainable longer-term enteral access with fewer side effects compared to the long-term nasogastric tube placement. Bleeding is a recognized complication of PEG placement, and many COVID-19 patients are on antiplatelets/anticoagulants, yet minimal data exist on the safety of PEG tube placement in this context. Methods A retrospective chart review identified patients who underwent PEG placement between January 2020 and January 2021 at a single institution. Success was defined as PEG placement and use to provide enteral nutrition with no complications requiring removal within 4 weeks. Results Thirty-six patients with and 104 age- and sex-matched patients without COVID-19 infection were included. More COVID-19 patients were obese, on anticoagulants, had low serum albumin levels and had a tracheostomy in place. Of those patients, 8.3% with COVID-19 developed PEG-related complications compared to 16.3% without (P = 0.28). PEG success rates in patients with and without COVID-19 were similar at 97.2% and 92.3%, respectively (P = 0.44). Conclusion PEG tube placement is comparatively safe in COVID-19 patients who need long-term enteral access.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
经皮内镜胃造口术在SARS-CoV-2感染患者中的安全性
背景:2019冠状病毒病(COVID-19)可导致依赖呼吸机的慢性呼吸衰竭,需要管饲。与长期鼻胃管置入相比,经皮内镜胃造口术(PEG)置入提供了更可持续的长期肠内通路,副作用更少。出血是公认的PEG置入并发症,许多COVID-19患者正在使用抗血小板/抗凝剂,但在这种情况下,关于PEG管置入安全性的数据很少。方法:回顾性分析了2020年1月至2021年1月在同一家机构接受PEG植入的患者。成功的定义是PEG放置和使用提供肠内营养,没有并发症需要在4周内移除。结果:纳入36例感染患者和104例年龄和性别匹配的未感染COVID-19患者。更多的COVID-19患者肥胖,服用抗凝血剂,血清白蛋白水平低,并进行了气管切开术。在这些患者中,8.3%的COVID-19患者出现了peg相关并发症,而没有出现peg相关并发症的患者为16.3% (P = 0.28)。合并和未合并COVID-19患者的PEG成功率相似,分别为97.2%和92.3% (P = 0.44)。结论:对于需要长期肠内通路的COVID-19患者,置PEG管是相对安全的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Gastroenterology Research
Gastroenterology Research GASTROENTEROLOGY & HEPATOLOGY-
自引率
0.00%
发文量
35
期刊最新文献
Risk Factors for Mortality in Patients With Strangulating Intestinal Obstruction Who Present With Septic Disseminated Intravascular Coagulation Prior to the Initiation of Treatment. Trends and Impact of Clostridioides difficile Infection on Thirty-Day Readmissions and Outcomes Following Coronary Artery Bypass Grafting: A Seven-Year National Analysis. Acyl-CoA Synthetase Long-Chain Family Member 4 in Liver Injury: Multidimensional Regulation and Therapeutic Potential. Early Therapeutic Response Predicts Outcome in Chronic Constipation: A Multicenter Prospective Observational Study. Clinical Efficacy of Early and Late Vedolizumab or Infliximab Interventions in Moderate Ulcerative Colitis: A Multicenter, Retrospective Cohort Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1